Navigation Links
The 'appetite-suppressing' effect of proteins explained
Date:7/6/2012

Frequently recommended in weight-loss diets, dietary proteins have proven effectiveness thanks to their appetite-suppressing effects. A team led by Gilles Mithieux, Director of Inserm's Unit 855 "Nutrition and the Brain" in Lyon, has managed to explain the biological mechanisms behind these properties. The researchers describe in detail the chain reactions triggered by digesting proteins, sending a 'satiety' message to the brain long after a meal. Their results, published on 5 July in the Cell review, will make it possible envisage improved care for obese or overweight patients.

The team of researchers from Inserm, CNRS and the Universit Clause Bernard Lyon 1 has managed to shed light on the sensation of fullness experienced several hours after a protein-rich meal. This sensation is explained by messages exchanged between the digestive system and the brain, initiated by the dietary proteins that are mainly found in meat, fish, eggs or even some cereal-based products.

In previous studies, researchers proved that consuming dietary proteins triggers glucose synthesis in the intestine, after periods of food assimilation (a function known as gluconeogenesis). The glucose that is released in the blood circulation (portal vein) is detected by the nervous system, which sends an "appetite-suppressing" signal to the brain. Best-known in the liver and kidneys from which it supplies other organs with sugar, gluconeogenesis in the intestine sends an "appetite-suppressing" message after meals, characteristic of the sensation of "fullness".

In this new study, the researchers managed to accurately describe how digesting proteins triggers a double-loop of chain reactions involving the ventral (via the vagus nerve) and dorsal (via the spinal cord) peripheral nervous systems.

The in-depth study of biological mechanisms identified the specific receptors (μ-opioid receptors ) found in the portal vein nervous system, at the outlet of the intestine. These receptors are inhibited by oligo-peptides, produced during protein digestion.

In an initial phase, the oglio-peptides act upon the μ-opioid receptors, which send a message through the vagus nerve and the spinal chord to areas of the brain specially-designed to receive these messages.

During a second phase, the brain sends a return-message that triggers gluconeogenesis via the intestine. The intestine then sends the "appetite-suppressing" message to areas of the brain that control food intake, such as the hypothalamus

  1. Consumption of dietary proteins
  2. Protein residues (oligo-peptides) travel to the intestine in the portal vein
  3. Recognition of oligo-peptides by μ-opioid receptors
  4. Receipt of peripheral signals
  5. Gluconeogenesis induction
  6. "Appetite-suppressing" message sent to brain

Identifying these receptors and their role in intestinal gluconeogenesis paves the way to explore new avenues for the treatment of obesity. The challenge is now to determine how to act on the μ-opioid receptors to control the fullness sensation over long periods. According to Gilles Mithieux, the leading author in the study: "If used too intensely, these receptors may become insensitive. A means of activating them 'moderately' must be found, thus retaining their long-term beneficial effects on controlling food intake".


'/>"/>

Contact: Inserm Press Office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert  

Related biology news :

1. Study offers new insights into the effects of stress on pregnancy
2. Scientists reconstruct pre-Columbian human effects on the Amazon Basin
3. The activity of a bacterial effector protein seen in molecular detail
4. Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors
5. New report examines effects of trees killed by bark beetles on wildfire
6. The effect of treatment with antibiotics and vaccination against Q fever in sheep
7. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
8. Lab tests show arthritis drug effective against global parasite
9. New evidence that many genes of small effect influence economic decisions and political attitudes
10. The gut could reveal effect of climate change on fish
11. WSU researchers say genes and vascular risk modify effects of aging on brain and cognition
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The 'appetite-suppressing' effect of proteins explained
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
Breaking Biology Technology: